IRIS
IAFFALDANO, PIETRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.217
AS - Asia 2.666
EU - Europa 2.513
SA - Sud America 653
AF - Africa 220
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 7
Totale 12.286
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.075
SG - Singapore 1.007
IT - Italia 908
CN - Cina 599
BR - Brasile 487
SE - Svezia 351
RU - Federazione Russa 326
HK - Hong Kong 323
VN - Vietnam 214
GB - Regno Unito 190
DE - Germania 183
FR - Francia 173
CI - Costa d'Avorio 114
FI - Finlandia 109
BD - Bangladesh 107
IN - India 81
AR - Argentina 75
CA - Canada 72
NL - Olanda 57
JP - Giappone 49
IQ - Iraq 44
UA - Ucraina 41
ID - Indonesia 35
MX - Messico 34
BE - Belgio 33
SA - Arabia Saudita 32
ZA - Sudafrica 27
PL - Polonia 26
EC - Ecuador 24
PK - Pakistan 24
TR - Turchia 24
UZ - Uzbekistan 23
PH - Filippine 22
AT - Austria 21
CO - Colombia 21
ES - Italia 21
VE - Venezuela 19
TN - Tunisia 15
EG - Egitto 13
JO - Giordania 11
KE - Kenya 11
LT - Lituania 11
CL - Cile 10
JM - Giamaica 10
MA - Marocco 9
MY - Malesia 9
AE - Emirati Arabi Uniti 8
AU - Australia 8
CZ - Repubblica Ceca 8
IL - Israele 8
IE - Irlanda 7
PY - Paraguay 7
ET - Etiopia 6
IR - Iran 6
NP - Nepal 6
PT - Portogallo 6
RO - Romania 6
AL - Albania 5
CR - Costa Rica 5
SN - Senegal 5
UY - Uruguay 5
BB - Barbados 4
CH - Svizzera 4
DK - Danimarca 4
DZ - Algeria 4
EE - Estonia 4
HU - Ungheria 4
KG - Kirghizistan 4
KZ - Kazakistan 4
LB - Libano 4
PS - Palestinian Territory 4
AZ - Azerbaigian 3
BG - Bulgaria 3
BO - Bolivia 3
DO - Repubblica Dominicana 3
EU - Europa 3
LV - Lettonia 3
MZ - Mozambico 3
OM - Oman 3
PA - Panama 3
A1 - Anonimo 2
GT - Guatemala 2
HN - Honduras 2
MK - Macedonia 2
NZ - Nuova Zelanda 2
RW - Ruanda 2
SV - El Salvador 2
TH - Thailandia 2
AM - Armenia 1
AO - Angola 1
BF - Burkina Faso 1
BJ - Benin 1
BT - Bhutan 1
BY - Bielorussia 1
GA - Gabon 1
GE - Georgia 1
GH - Ghana 1
GL - Groenlandia 1
GM - Gambi 1
GR - Grecia 1
Totale 12.261
Salva come PNG Salva come JPEG
Città #
Ashburn 695
Fairfield 616
Singapore 510
Chandler 431
Woodbridge 378
Hong Kong 323
Dallas 318
San Jose 315
Milan 280
Houston 279
Nyköping 270
Seattle 256
Ann Arbor 240
Cambridge 211
Beijing 178
Wilmington 176
Abidjan 114
Los Angeles 108
Lauterbourg 99
New York 97
Lawrence 81
Jacksonville 77
Roxbury 71
Bari 70
Helsinki 69
Rome 69
Ho Chi Minh City 67
Boardman 64
Brooklyn 56
Columbus 54
São Paulo 54
Council Bluffs 53
Des Moines 49
Santa Clara 47
Buffalo 46
Chicago 45
Tokyo 44
Munich 42
Hanoi 41
Nanjing 41
London 37
Princeton 37
Moscow 36
Frankfurt am Main 35
Brussels 33
Amsterdam 32
Falkenstein 31
Nuremberg 31
Orem 31
Inglewood 30
Toronto 30
San Diego 27
Guangzhou 26
North Bergen 26
Figino 22
Jakarta 20
Norwalk 20
Paris 20
Atlanta 18
Salt Lake City 18
Warsaw 18
Rio de Janeiro 17
Shanghai 17
Johannesburg 16
Montreal 16
Baghdad 15
Poplar 15
Jeddah 14
Tashkent 14
Turin 14
Dong Ket 13
Naples 13
Stockholm 13
Tianjin 13
Dhaka 12
San Francisco 12
Bisceglie 11
Chennai 11
Denver 11
Haiphong 11
Lahore 11
Phoenix 11
Quito 11
Shenyang 11
Taranto 11
Amman 10
Buenos Aires 10
Cagliari 10
Manchester 10
Nanchang 10
Washington 10
Boston 9
Da Nang 9
Dearborn 9
Miami 9
Nairobi 9
Vienna 9
Belo Horizonte 8
Bologna 8
Medellín 8
Totale 8.063
Salva come PNG Salva come JPEG
Nome #
Signs and symptoms of COVID-19 in patients with multiple sclerosis 221
Correction to: Disability assessment using Google Maps (Neurological Sciences, (2022), 43, 2, (1007-1014), 10.1007/s10072-021-05389-7) 217
RELATIONSHIP OF COGNITIVE PERFORMANCES AND EMPLOYMENT STATUS IN PEOPLE WITH RELAPSING MULTIPLE SCLEROSIS 211
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis 205
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis 197
Prognostic indicators in pediatric clinically isolated syndrome 190
Computer-assisted rehabilitation of attention in pediatric multiple sclerosis and ADHD patients: a pilot trial 186
Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort 185
Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies 183
Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients 180
Comparative effectiveness of natalizumab and fingolimod treatment on cognitive functions in relapsing multiple sclerosis. ECTRIMS 2016 - Poster Session 2 177
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register 171
Lymphocyte count and body mass index as biomarkers of early treatment response in a multiple sclerosis dimethyl fumarate-treated cohort 163
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. 160
Computer-assisted rehabilitation of attention in patients with multiple sclerosis: results of a randomized, double-blind trial. 159
Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. 157
Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study. 150
SCLEROSI MULTIPLA E LAVORO: DATI PRELIMINARI 149
Load-dependent dysfunction of the putamen during attentional processing in patients with clinically isolated syndrome suggestive of multiple sclerosis. 146
Treatment decisions in multiple sclerosis-insights from real-world observational studies 145
Verbal fluency deficits in clinically isolated syndrome suggestive of multiple sclerosis. 142
Multiple sclerosis registries in Europe – An updated mapping survey 141
Sclerosi Multipla e Lavoro: dati preliminari 140
Predictors of long-term disability accrual in relapse-onset multiple sclerosis 139
Multiple Sclerosis Progression and Relapse Activity in Children 137
Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide 137
Treating multiple sclerosis with natalizumab. 134
Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis 134
Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years 128
DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France 126
Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study 124
Detection of disability worsening in relapsing-remitting multiple sclerosis patients. A real-world roving EDSS-Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register 124
Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis 123
Emotional and neutral verbal memory impairment in Multiple Sclerosis 122
Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMOSD by a Semiquantitative Ratiometric Method 122
The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. 121
The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis. 121
COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context 121
Real-Life Experience of the Effects of Cladribine Tablets on Lymphocyte Subsets and Serum Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis Patients 120
The role of neutralizing antibodies to interferon-β as a biomarker of persistent MRI activity in multiple sclerosis: a 7-year observational study 120
Geographical variations in sex ratio trends over time in multiple sclerosis. 119
Safety profile of Tysabri: international risk management plan 118
Neuromyelitis optica spectrum disorders associated with systemic sclerosis: a case report and literature review 118
Low serum urate levels are associated to female gender in multiple sclerosis patients. 117
Dengue fever in a multiple sclerosis patient taking Ocrelizumab 117
Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica 116
Effect of cladribine on neuronal apoptosis: New insight of in vitro study in multiple sclerosis therapy 116
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study 116
Predictors of unemployment status in people with relapsing multiple sclerosis: a single center experience 116
Durvalumab and multiple sclerosis: a causal link or simple unmasking? 115
Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients 114
Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome 114
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study 114
Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration 112
Clinical and biological predictors of Cladribine effectiveness in Multiple Sclerosis: A real-world, single Centre study considering a two-year interval from year-2 dosing 109
null 109
Natural history of multiple sclerosis: have available therapies impacted long-term prognosis? 109
Disability assessment using Google Maps 109
First evidence of in vivo pro-angiogenic activity of cerebrospinal fluid samples from multiple sclerosis patients 108
Defining the course of tumefactive multiple sclerosis: a large retrospective multicentre study 108
A Randomized Computer-Assisted Rehabilitation Trial of Attention in Pediatric Multiple Sclerosis: A Post Hoc Analysis 108
Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders Register 107
Postmarketing evidence of disease-modifying drugs in multiple sclerosis 106
Predictors and dynamics of postpartum relapses in women with multiple sclerosis. 103
Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis 101
Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries 99
Impact of depression on the perception of fatigue and information processing speed in a cohort of multiple sclerosis patients 98
Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors 98
Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network 97
Anxiety state affects information processing speed in patients with multiple sclerosis 94
Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis 92
Age-dependent response to initial highly effective treatment in relapsing multiple sclerosis 92
Assessing long-term effectiveness of MS treatment - a matter of debate 90
Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression 86
Natalizumab reduces serum pro-angiogenic activity in MS patients 85
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study 85
A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis 83
Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study 83
Big Multiple Sclerosis Data network: an international registry research network 82
Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network 81
Active and non-active secondary progressive multiple sclerosis patients exhibit similar disability progression: results of an Italian MS registry study (ASPERA) 80
Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis 80
Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis 79
The impact of neutralizing antibodies on the risk of disease worsening in interferon β-treated relapsing multiple sclerosis: a 5 year post-marketing study. 78
Interdisciplinary approach to opportunistic infections: staphylococcal meningitis in a patient with multiple sclerosis on treatment with dimethyl fumarate 75
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis 75
Risk of Getting COVID-19 in People With Multiple Sclerosis 75
Serum N-acetyl-aspartate in Relapsing Remitting Multiple Sclerosis 74
null 73
Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study 73
Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register 73
Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study 72
The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis 69
null 68
Siponimod from fingolimod direct switch in patients transitioning in secondary progressive multiple sclerosis: A single center case series 68
Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry 67
null 67
null 65
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients 64
Real-life impact of early interferonbeta therapy in relapsing multiple sclerosis 61
Totale 11.708
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.340
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.340
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022754 61 72 21 23 49 87 34 44 51 48 117 147
2022/20231.102 158 170 88 87 128 131 20 120 151 4 26 19
2023/2024442 41 54 29 24 41 95 16 25 6 30 11 70
2024/20252.094 149 38 126 74 68 153 223 187 126 116 291 543
2025/20265.336 653 362 478 473 540 381 447 192 545 506 182 577
2026/2027163 163 0 0 0 0 0 0 0 0 0 0 0
Totale 12.739